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Supplementary Figure S1:

91R binding to CCR9-silenced MOLT-4 cells
Untreated, control shRNA-, hCCR9 shRNA1-or hCCR9 shRNA2-infected MOLT-4 cells were analyzed by flow cytometry using 91R or isotype control antibody. One representative experiment is shown of three.
Supplementary Materials and Methods:
Lentivirus-mediated shRNA silencing shRNAi lentiviral particles were prepared using the lentivirus-compatible vectors pCMV-dR8.91 and pMD2.G (Addgene); and non-target-shRNA control or CCR9-shRNA (Mission SHCLNG_10051011MN,Sigma-Aldrich). Each shRNA vector was cotransfected with pCMV-dR8.91 and pMD2.G in the HEK-293T cell line (using Opti-MEM, Invitrogen). At 48 h post-transfection, medium containing viruses was collected and filtered through a 0.45 μm filter (Tiscornia et al. 2006 ). Viral titer was determined by standard procedures.
MOLT-4 cells (2 x 10
5 ) were plated in 1 ml complete medium 24 h before infection with 350 plaque-forming units (pfu) of the indicated pseudovirus (48 h).
Cells were cultured for an additional 7 days in complete medium supplemented with puromycin (2 μg/ml) to select lentivirus-infected cells prior to flow cytometry analysis of CCR9 expression using 91R antibody.
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